Abstract
Despite promising anti-leukemic activity of MCL-1 inhibitors in preclinical studies of acute myeloid leukemia (AML), their progress through clinical evaluation has in part been challenged by limited knowledge of patient subgroups suitable for treatment. To stratify patients with AML for MCL-1 inhibitor-based treatment, we evaluated the sensitivity of 42 primary AML samples to MCL-1 inhibitor MIK665 (S64315) and contrasted their molecular profiles. We observed that MIK665 sensitive samples had a more differentiated phenotype, whereas resistant samples displayed higher levels of ABCB1 (MDR1) and the anti-apoptotic protein BCL-XL. Further evaluation revealed that ABCB1 expression has good predictive performance in identifying MIK665 primary resistant samples. To induce sensitivity, we treated MIK665-resistant samples with ABCB1 inhibitor elacridar, BCL-XL inhibitor A1331852, or BCL-2 inhibitor venetoclax in combination with MIK665. While combinations with elacridar and A1331852 were not effective, the combination of MIK665 and venetoclax effectively eliminated AML blasts compared to either of the agents alone. Additionally, the combination restored sensitivity of samples with primary venetoclax resistance. Overall, this study indicates that elevated ABCB1 expression is a potential predictor of resistance to MIK665 in AML, and that a combination of MIK665 with venetoclax may be effective for overcoming resistance to either MCL-1 or BCL-2 inhibition.
Competing Interest Statement
Sofia Aakko is currently an employee of Faron Pharmaceuticals, and Eric Durand is an employee of Owkin. During their participation in this study, Eric Durand, Janghee Woo, Heiko Maacke, and Ensar Halilovic were employees and shareholders of Novartis. Caroline Heckman received research funding from Novartis related to this work and has received unrelated research funding from BMS/Celgene, Kronos Bio, Oncopeptides, Orion Pharma, WntResearch, and the Innovative Medicines Initiative 2 project HARMONY, plus personal fees from Amgen and Autolus. Mika Kontro has received personal fees from Astellas Pharma, AbbVie, Bristol-Myers Squibb, Faron Pharmaceuticals, Novartis and Pfizer outside the submitted work. Kimmo Porkka has received unrelated research funding from Incyte, Novartis and Roche.
Funding Statement
This work was supported by funding received by Caroline Heckman from Novartis, the Research Council of Finland (grant no. 334781, 352265, 357686, and 320185), the Sigrid Juselius Foundation, and the Cancer Foundation Finland.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics committee/IRB of the Helsinki University Hospital Comprehensive Cancer Center gave ethical approval for this work (permit numbers 239/13/03/00/2010 and 303/13/03/01/2011).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Competing interests: Sofia Aakko is currently an employee of Faron Pharmaceuticals, and Eric Durand is an employee of Owkin. During their participation in this study, Eric Durand, Janghee Woo, Heiko Maacke, and Ensar Halilovic were employees and shareholders of Novartis. Caroline Heckman received research funding from Novartis related to this work and has received unrelated research funding from BMS/Celgene, Kronos Bio, Oncopeptides, Orion Pharma, WntResearch, and the Innovative Medicines Initiative 2 project HARMONY, plus personal fees from Amgen and Autolus. Mika Kontro has received personal fees from Astellas Pharma, AbbVie, Bristol-Myers Squibb, Faron Pharmaceuticals, Novartis and Pfizer outside the submitted work. Kimmo Porkka has received unrelated research funding from Incyte, Novartis and Roche.
Data Availability
All data produced in the present work are contained in the manuscript and its supplementary data and are available upon reasonable request to the corresponding author.
